A clinical study by Pagan et al. explored the effects of bosutinib in dementia with Lewy bodies (DLB) patients and noted that the drug was safe and well tolerated in DLB patients, with attenuation of alpha‐synuclein and dopamine levels in CSF, at approximately the least efficacious dose of bosutinib [103]. This evidence concerns the gene SNCA and Lewy body dementia.